388 related articles for article (PubMed ID: 23532240)
1. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial.
Lamas GA; Goertz C; Boineau R; Mark DB; Rozema T; Nahin RL; Lindblad L; Lewis EF; Drisko J; Lee KL;
JAMA; 2013 Mar; 309(12):1241-50. PubMed ID: 23532240
[TBL] [Abstract][Full Text] [Related]
2. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT).
Escolar E; Lamas GA; Mark DB; Boineau R; Goertz C; Rosenberg Y; Nahin RL; Ouyang P; Rozema T; Magaziner A; Nahas R; Lewis EF; Lindblad L; Lee KL
Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):15-24. PubMed ID: 24254885
[TBL] [Abstract][Full Text] [Related]
3. The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT).
Ujueta F; Arenas IA; Escolar E; Diaz D; Boineau R; Mark DB; Golden P; Lindblad L; Kim H; Lee KL; Lamas GA
J Diabetes Complications; 2019 Jul; 33(7):490-494. PubMed ID: 31101487
[TBL] [Abstract][Full Text] [Related]
4. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy.
Lamas GA; Boineau R; Goertz C; Mark DB; Rosenberg Y; Stylianou M; Rozema T; Nahin RL; Terry Chappell L; Lindblad L; Lewis EF; Drisko J; Lee KL
Am Heart J; 2014 Jul; 168(1):37-44.e5. PubMed ID: 24952858
[TBL] [Abstract][Full Text] [Related]
5. Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT).
Escolar E; Ujueta F; Kim H; Mark DB; Boineau R; Nahin RL; Goertz C; Lee KL; Anstrom KJ; Lamas GA
J Diabetes Complications; 2020 Aug; 34(8):107616. PubMed ID: 32446881
[TBL] [Abstract][Full Text] [Related]
6. Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial.
Lamas GA; Boineau R; Goertz C; Mark DB; Rosenberg Y; Stylianou M; Rozema T; Nahin RL; Lindblad L; Lewis EF; Drisko J; Lee KL;
Ann Intern Med; 2013 Dec; 159(12):797-805. PubMed ID: 24490264
[TBL] [Abstract][Full Text] [Related]
7. Design of the Trial to Assess Chelation Therapy (TACT).
Lamas GA; Goertz C; Boineau R; Mark DB; Rozema T; Nahin RL; Drisko JA; Lee KL
Am Heart J; 2012 Jan; 163(1):7-12. PubMed ID: 22172430
[TBL] [Abstract][Full Text] [Related]
8. Quality-of-life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the trial to assess chelation therapy randomized trial.
Mark DB; Anstrom KJ; Clapp-Channing NE; Knight JD; Boineau R; Goertz C; Rozema TC; Liu DM; Nahin RL; Rosenberg Y; Drisko J; Lee KL; Lamas GA;
Circ Cardiovasc Qual Outcomes; 2014 Jul; 7(4):508-16. PubMed ID: 24987051
[TBL] [Abstract][Full Text] [Related]
9. Differential Outcomes With Edetate Disodium-Based Treatment Among Stable Post Anterior vs. Non-Anterior Myocardial Infarction Patients.
Lewis EF; Ujueta F; Lamas GA; Roberts RS; Mark DB; Nahin RL; Goertz C; Stylianou M; Lee KL
Cardiovasc Revasc Med; 2020 Nov; 21(11):1389-1395. PubMed ID: 32303436
[TBL] [Abstract][Full Text] [Related]
10. The trial to assess chelation therapy 2 (TACT2): Rationale and design.
Lamas GA; Anstrom KJ; Navas-Acien A; Boineau R; Kim H; Rosenberg Y; Stylianou M; Jones TLZ; Joubert BR; Santella RM; Escolar E; Aude YW; Fonseca V; Elliott T; Lewis EF; Farkouh ME; Nathan DM; Mon AC; Gosnell L; Newman JD; Mark DB;
Am Heart J; 2022 Oct; 252():1-11. PubMed ID: 35598636
[TBL] [Abstract][Full Text] [Related]
11. Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT).
Issa OM; Roberts R; Mark DB; Boineau R; Goertz C; Rosenberg Y; Lewis EF; Guarneri E; Drisko J; Magaziner A; Lee KL; Lamas GA
Am Heart J; 2018 Jan; 195():70-77. PubMed ID: 29224648
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.
Gencer B; Mach F; Murphy SA; De Ferrari GM; Huber K; Lewis BS; Ferreira J; Kurtz CE; Wang H; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
JAMA Cardiol; 2020 Aug; 5(8):952-957. PubMed ID: 32432684
[TBL] [Abstract][Full Text] [Related]
13. Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients.
Peguero JG; Arenas I; Lamas GA
Trends Cardiovasc Med; 2014 Aug; 24(6):232-40. PubMed ID: 25106084
[TBL] [Abstract][Full Text] [Related]
14. Chelation therapy for ischemic heart disease: a randomized controlled trial.
Knudtson ML; Wyse DG; Galbraith PD; Brant R; Hildebrand K; Paterson D; Richardson D; Burkart C; Burgess E;
JAMA; 2002 Jan 23-30; 287(4):481-6. PubMed ID: 11798370
[TBL] [Abstract][Full Text] [Related]
15. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
[TBL] [Abstract][Full Text] [Related]
16. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
Murphy SA; Pedersen TR; Gaciong ZA; Ceska R; Ezhov MV; Connolly DL; Jukema JW; Toth K; Tikkanen MJ; Im K; Wiviott SD; Kurtz CE; Honarpour N; Giugliano RP; Keech AC; Sever PS; Sabatine MS
JAMA Cardiol; 2019 Jul; 4(7):613-619. PubMed ID: 31116355
[TBL] [Abstract][Full Text] [Related]
17. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Nicholls SJ; Kastelein JJ; Schwartz GG; Bash D; Rosenson RS; Cavender MA; Brennan DM; Koenig W; Jukema JW; Nambi V; Wright RS; Menon V; Lincoff AM; Nissen SE;
JAMA; 2014 Jan; 311(3):252-62. PubMed ID: 24247616
[TBL] [Abstract][Full Text] [Related]
18. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.
Verma S; Bain SC; Buse JB; Idorn T; Rasmussen S; Ørsted DD; Nauck MA
JAMA Cardiol; 2019 Dec; 4(12):1214-1220. PubMed ID: 31721979
[TBL] [Abstract][Full Text] [Related]
19. Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.
Sesso HD; Christen WG; Bubes V; Smith JP; MacFadyen J; Schvartz M; Manson JE; Glynn RJ; Buring JE; Gaziano JM
JAMA; 2012 Nov; 308(17):1751-60. PubMed ID: 23117775
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.
Deedwania P; Murphy SA; Scheen A; Badariene J; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
JAMA Cardiol; 2021 Feb; 6(2):139-147. PubMed ID: 32785614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
